Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial

Journal:

The Lancet Neurology

Published:

2025-08-14

DOI:

10.1016/s1474-4422(25)00225-x

Affiliations:

25

Authors:

59

Go to article

Institutions	Authors	Share
Scholar Rock, United States of America (USA)	6.000000	0.24
I-Motion Institute, France	2.000000	0.08
Catholic University of the Sacred Heart (UCSC), Italy	1.500000	0.06
Johns Hopkins Medicine (JHM), JHU, United States of America (USA)	1.000000	0.04
University of Milan (UNIMI), Italy	1.000000	0.04
The University of Utah (Utah), United States of America (USA)	1.000000	0.04
Stanford University, United States of America (USA)	1.000000	0.04
University Medical Center Utrecht (UMC Utrecht), Netherlands	1.000000	0.04
Essen University Hospital, Germany	1.000000	0.04
St. Jude Children's Research Hospital (St. Jude), United States of America (USA)	1.000000	0.04
Children's Hospital, CHU-Toulouse, France	1.000000	0.04
Boston Children's Hospital (BCH), United States of America (USA)	1.000000	0.04
University Medical Center Freiburg, Germany	1.000000	0.04
Helen DeVos Children's Hospital, United States of America (USA)	1.000000	0.04
Ann and Robert H. Lurie Children's Hospital of Chicago, NU, United States of America (USA)	0.500000	0.02
Agostino Gemelli University Polyclinic, Italy	0.500000	0.02
Catholic University of Leuven (KU Leuven), Belgium	0.500000	0.02
Children's Medical Center Dallas, United States of America (USA)	0.500000	0.02
NIHR Oxford Biomedical Research Centre (OxBRC), United Kingdom (UK)	0.500000	0.02
Northwestern University (NU), United States of America (USA)	0.500000	0.02
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	0.500000	0.02
University Hospitals Leuven (UZ Leuven), Belgium	0.500000	0.02
University Hospital of Liege, Belgium	0.500000	0.02

Interested in Neurosciences?